A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

Sponsors and Collaborators
Lpath, Inc.

Contact
Sumanta K Pal, MD
626-256-4673
spal@coh.org

Principal Investigator
France LaPierre-Holme, Executive Director of Development at Lpath

ClinicalTrials.gov Identifier
NCT01762033